Provide updated results for Study 1100
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 4 Jun 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“2Q 2021 –Updated results with new patients and additional follow up expected”
What we found
Evidence strength A What the grades mean
The company presented updated clinical results for Study 1100 during the first half of 2021, specifically at the ASCO Annual Meeting held in June 2021, meeting the second-quarter deadline.
-
A Nanobiotix S.A. 6-K filed 2021-07-20
“Presented Updated Results from Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-In-Class Radioenhancer NBTXR3 at 2021 Annual Meeting of The American Society for Clinical Oncology (ASCO)” ✓ confirmed on the page
-
A Nanobiotix S.A. 6-K filed 2021-09-08
“Following positive data from ongoing Study 1100 presented in H1 2021 showing that NBTXR3 in combination with anti-PD-1 resulted in tumor regression in 76.9% of evaluable patients” ✓ confirmed on the page
Market reaction: the shares moved -6.3% against the S&P 500 over the three sessions around the disclosure (7 Sep 2021 to 10 Sep 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Provide
- Deliverable
- Study 1100 updated results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Nanobiotix S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-NBTX-021369 · Corrections policy